Xanthohumol COX inhibitor

Cat.No.S7889

Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. This compound inhibits diacylglycerol acyltransferase 1 (DGAT1) and DGAT2 with both IC50 of 40 μM. It is also a potent antiviral agent against a series of DNA and RNA viruses. This chemical induces growth inhibition and apoptosis in cancer cells. Phase 1.
Xanthohumol COX inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 354.4

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 354.4 Formula

C21H22O5

Storage (From the date of receipt)
CAS No. 6754-58-1 Download SDF Storage of Stock Solutions

Synonyms N/A Smiles CC(=CCC1=C(C(=C(C=C1O)OC)C(=O)C=CC2=CC=C(C=C2)O)O)C

Solubility

In vitro
Batch:

DMSO : 70 mg/mL (197.51 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 70 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
COX-1 [1]
COX-2 [1]
DGAT1 [5]
(Cell-free assay)
40 μM
DGAT2 [5]
(Cell-free assay)
40 μM
In vitro

Xanthohumol inhibits Cyp1A activity and induces QR activity in mouse hepatoma cell culture. This compound scavenges reactive oxygen species and inhibits superoxide anion radical and nitric oxide production. In addition, it prevents carcinogenesis via inhibition of DNA synthesis and induction of cell cycle arrest in S phase, apoptosis, and cell differentiation. [1] It shows potent anti-HIV-1 activity. [2]

Kinase Assay
Inhibition of Cox Activity
Inhibition of Cox-1 activity is measured by monitoring oxygen consumption during the conversion of arachidonic acid to PGs using a Clark-type O2-electrode. The reaction mixture contains ∼0.2 units Cox-1 in 100 μL of microsome fraction derived from ram seminal vesicles as a crude source of Cox-1 (specific activity 0.2–1 units/mg protein) or 0.23 units of recombinant human Cox-2 (specific activity 43 units/mg protein). For calculation, the rate of O2 consumption is compared with a DMSO control (100% activity). CP-16171, a nonsteroidal anti-inflammatory drug, is used as positive inhibitory substance for Cox-1 activity with an IC50 of 0.35 ± 0.05 μM (n = 2). Alternatively, nimesulide, a Cox-2 specific inhibitor, inhibits Cox-2 activity by 52 ± 5.7% (n = 2) at a concentration of 50 μM.
In vivo

In CETP-Tg mice, xanthohumol (p.o.) prevents cholesterol accumulation leading to atherosclerosis. [3] In TRAMP mice, this compound induces a decrease in the average weight of the urogenital (UG) tract, delays advanced tumor progression and inhibits the growth of poorly differentiated prostate carcinoma. [4]

References
  • [4] https://pubmed.ncbi.nlm.nih.gov/22952060/
  • [5] https://pubmed.ncbi.nlm.nih.gov/19132064/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06225258 Recruiting
Septic Shock|Pneumonia|ARDS
Medical University of Lublin
May 9 2023 Phase 2
NCT03735420 Active not recruiting
Healthy
National University of Natural Medicine|Oregon State University|Pacific Northwest National Laboratory
August 12 2019 Phase 1
NCT01367431 Completed
Metabolic Syndrome
Oregon State University|Oregon Health and Science University|National Center for Complementary and Integrative Health (NCCIH)
August 2011 --

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Signaling Pathway Map